CONMED Management
Management criteria checks 1/4
CONMED's CEO is Pat Beyer, appointed in Jan 2025, has a tenure of 1.5 years. total yearly compensation is $7.63M, comprised of 11.7% salary and 88.3% bonuses, including company stock and options. directly owns 0.036% of the company’s shares, worth $353.69K. The average tenure of the management team and the board of directors is 1.5 years and 6.7 years respectively.
Key information
Pat Beyer
Chief executive officer
US$7.6m
Total compensation
| CEO salary percentage | 11.67% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.04% |
| Management average tenure | 1.5yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Narrative Update • Jun 18
CNMD: Refocused Surgical Portfolio And Buybacks Will Test Medtech Reset
Analysts have reset their price target on CONMED to $40, down from $52, citing a broader reassessment of medtech valuations in a year with fewer product cycles, along with rising concerns around healthcare utilization and inflation. Analyst Commentary Recent commentary on CONMED highlights that the lower US$40 price target sits within a broader reset for medtech valuations, rather than being tied to a single company specific issue.
Narrative Update • Jun 04
CNMD: Reset Medtech Expectations Will Set Stage For 2026 Guidance Reassessment
Analysts have trimmed their price targets on CONMED, with figures such as BofA cutting its target to $40 and another firm moving to $39. This reflects a reset in medtech valuations, as well as concerns around product execution and limited near term catalysts.Narrative Update • May 20
CNMD: Execution And Margin Stability Will Be Tested In Medtech Reset
Analysts have reduced CONMED's fair value estimate and price target to $40 from $52. They cite a reset in medtech valuations, concerns around product cycles and utilization, and a lower assumed future P/E multiple, while keeping revenue growth and profit margin assumptions broadly steady.Narrative Update • May 01
CNMD: Execution Repairs And Margin Stability Will Support Future Upside
Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.Narrative Update • Apr 17
CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile
Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.Narrative Update • Apr 02
CNMD: Execution Rebound And Margin Focus Will Support Future Upside
The analyst price target for CONMED has been reduced by $3 to $52, as analysts factor in a slightly higher discount rate and a lower future P/E multiple while still modeling modestly higher revenue growth and profit margins, and acknowledging recent downgrades that highlight concerns around execution and a lack of near term catalysts. Analyst Commentary Recent research on CONMED reflects a mixed setup, with some analysts focused on execution risks and a lack of clear near term catalysts, while others maintain a more balanced stance that supports a mid range valuation and steady expectations.Narrative Update • Mar 18
CNMD: Execution Concerns And Leadership Transition Will Shape Balanced Risk Profile
Narrative Update: CONMED Price Target Shift The analyst price target for CONMED has been revised from $42 to $39, with analysts pointing to execution missteps, weaker sentiment around the AirSeal product, and a lack of clear near term catalysts as key reasons for the adjustment. Analyst Commentary Recent Street research on CONMED has tilted more cautious, with several bearish analysts highlighting execution risk, questions around AirSeal, and a limited near term catalyst path to re-rate the shares.Narrative Update • Mar 04
CNMD: Portfolio Refocus And Leadership Change Will Shape Balanced Risk Profile
Narrative Update on CONMED Analysts kept their $42 price target for CONMED unchanged. They cited slightly higher assumed revenue growth and profit margins along with a modestly lower discount rate and future P/E, which together support a steady valuation view despite ongoing sector volatility highlighted in recent research.Narrative Update • Feb 17
CNMD: Portfolio Refocus And Higher Future P/E Will Support Returns
Analysts maintained their fair value estimate for CONMED at $55.00 and refreshed their price target framework to incorporate more conservative assumptions for revenue growth and profit margins, while also reflecting a higher future P/E multiple. Analyst Commentary Bullish analysts appear comfortable holding their US$55.00 fair value estimate for CONMED while updating models to reflect more conservative assumptions for revenue growth and margins.Narrative Update • Feb 03
CNMD: Future Portfolio Shift And Capital Moves Signal Balanced Risk Profile
Analysts have reduced their price target on CONMED to US$42 from US$55, citing a higher discount rate, more conservative revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple in their updated models. Analyst Commentary Bearish analysts are using the lower US$42 price target as a signal that they see less room for upside in CONMED at current levels, especially when they factor in higher discount rates and more cautious revenue assumptions.
Narrative Update • Jan 19
CNMD: Gastro Exit And Buybacks Will Support Future Margin Expansion
Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it. Analyst Commentary Bullish Takeaways Bullish analysts see the steady fair value estimate of $48.40, together with the slightly lower discount rate, as a sign that their view on CONMED’s risk profile and long term earnings power remains intact even after recent fine tuning.Narrative Update • Jan 05
CNMD: Gastro Exit And Buybacks Will Support Margin Expansion Ahead
Analysts have trimmed their price target for CONMED to about US$48.40 from roughly US$54.00, pointing to slightly lower growth assumptions and a reduced future P/E multiple, partly balanced by a marginally higher profit margin outlook. What's in the News CONMED plans to exit its gastroenterology product lines, aiming to focus resources on core areas such as minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair (Key Developments).Narrative Update • Dec 20
CNMD: Focused Surgical Portfolio And Buybacks Will Support Stronger Future Returns
Analysts have lowered their price target on CONMED from 80.00 dollars to 55.00 dollars, citing slightly slower expected revenue growth and a higher discount rate that more than offset improved margin and valuation assumptions. What's in the News CONMED will exit its gastroenterology product lines to focus resources on core areas including minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.Seeking Alpha • Dec 15
Conmed Taking On More Pain In The Pursuit Of Future Gain
Summary Conmed (CNMD) shares are nearing decade lows despite credible progress with supply issues and ongoing efforts to shift toward higher-growth, higher-margin products. Management accelerated the exit from the lower-margin gastroenterology business, trading near-term revenue and EPS dilution for an 80bp margin boost and improved strategic focus. AirSeal's attach rate remains pressured by Intuitive Surgical's dv5, but upside exists from non-robotic procedures and OUS and ACS market expansion. CNMD appears undervalued on DCF and EV/revenue, but lacks near-term growth catalysts and remains a high-risk value play pending tangible restructuring results. Read the full article on Seeking AlphaNarrative Update • Dec 06
CNMD: Margin Expansion And Buyback Program Will Drive Strong Future Returns
Analysts have nudged their price target on CONMED slightly higher to $54, citing modestly lower discount rate and revenue growth assumptions, offset by a slightly improved profit margin outlook and a marginally lower future P/E multiple that together support a stable valuation profile. Analyst Commentary Analyst views on CONMED remain balanced, with recent model tweaks reflecting a more nuanced outlook on growth, profitability, and valuation.Narrative Update • Nov 22
CNMD: Margin Initiatives And Robust Buyback Will Drive Long-Term Shareholder Value
CONMED's analyst price target has been reduced from $56 to $54 per share, as analysts cite modest cuts to growth and profit outlooks, along with slightly higher discount rates following recent sector updates. Analyst Commentary Analysts have provided a range of perspectives on CONMED’s outlook based on recent developments in company performance and sector trends.Narrative Update • Nov 07
CNMD: Improving Profit Margins And Robust Buyback Program Will Drive Shareholder Value
CONMED's analyst price target has been lowered from $61 to $56. This change reflects a more cautious stance as analysts point to expectations of slower revenue growth and a higher discount rate, despite improvements in underlying profit margins and future valuation multiples.Analysis Article • Oct 06
These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Sep 12
CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) has announced that it will pay a dividend of $0.20 per share on the 3rd of October...Analysis Article • Aug 08
CONMED's (NYSE:CNMD) Solid Profits Have Weak Fundamentals
CONMED Corporation ( NYSE:CNMD ) just reported some strong earnings, and the market reacted accordingly with a healthy...Analysis Article • Jul 03
Are Investors Undervaluing CONMED Corporation (NYSE:CNMD) By 49%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, CONMED fair value estimate is US$107 Current share price of...Analysis Article • May 24
CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 3rd of July. This means the dividend yield will be...Analysis Article • May 17
CONMED Corporation's (NYSE:CNMD) Shares Bounce 26% But Its Business Still Trails The Market
Those holding CONMED Corporation ( NYSE:CNMD ) shares would be relieved that the share price has rebounded 26% in the...Analysis Article • Mar 31
Is CONMED (NYSE:CNMD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 28
Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse
Summary Conmed's ambitious revenue growth targets and ongoing operational issues have led to underperformance, with shares down 10% since my last update and ongoing concerns about growth, margins, and tariffs. Despite a decent Q4, Conmed's 2025 guidance was disappointing, with no margin expansion expected and a need to remediate supply and inventory issues. The threatened 25% tariff on goods imported from Mexico could severely affect earnings, adding to the company's existing operational and competitive challenges. While Conmed's valuation appears undemanding, significant risks and uncertainties suggest it may be prudent to wait for clearer signs of improvement before investing. Read the full article on Seeking AlphaAnalysis Article • Feb 28
CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 4th of April. This means the dividend yield will...Analysis Article • Feb 08
CONMED Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that CONMED Corporation ( NYSE:CNMD ) filed its full-year result this time last week...Analysis Article • Jan 20
CONMED Corporation (NYSE:CNMD) Looks Inexpensive But Perhaps Not Attractive Enough
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Analysis Article • Jan 01
Is Now The Time To Look At Buying CONMED Corporation (NYSE:CNMD)?
CONMED Corporation ( NYSE:CNMD ), might not be a large cap stock, but it saw a decent share price growth of 11% on the...Analysis Article • Dec 13
CONMED (NYSE:CNMD) Has Affirmed Its Dividend Of $0.20
The board of CONMED Corporation ( NYSE:CNMD ) has announced that it will pay a dividend on the 3rd of January, with...Analysis Article • Nov 25
Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Nov 07
CONMED's (NYSE:CNMD) Earnings Are Weaker Than They Seem
Unsurprisingly, CONMED Corporation's ( NYSE:CNMD ) stock price was strong on the back of its healthy earnings report...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$55m |
| Dec 31 2025 | US$8m | US$891k | US$47m |
| Sep 30 2025 | n/a | n/a | US$64m |
| Jun 30 2025 | n/a | n/a | US$110m |
| Mar 31 2025 | n/a | n/a | US$119m |
| Dec 31 2024 | US$4m | US$585k | US$132m |
| Sep 30 2024 | n/a | n/a | US$132m |
| Jun 30 2024 | n/a | n/a | US$99m |
| Mar 31 2024 | n/a | n/a | US$82m |
| Dec 31 2023 | US$3m | US$549k | US$64m |
| Sep 30 2023 | n/a | n/a | US$58m |
| Jun 30 2023 | n/a | n/a | US$88m |
| Mar 31 2023 | n/a | n/a | -US$94m |
| Dec 31 2022 | US$4m | US$501k | -US$81m |
| Sep 30 2022 | n/a | n/a | -US$83m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | US$68m |
| Dec 31 2021 | US$3m | US$537k | US$63m |
| Sep 30 2021 | n/a | n/a | US$62m |
| Jun 30 2021 | n/a | n/a | US$54m |
| Mar 31 2021 | n/a | n/a | US$13m |
| Dec 31 2020 | US$2m | US$477k | US$10m |
| Sep 30 2020 | n/a | n/a | US$311k |
| Jun 30 2020 | n/a | n/a | US$431k |
| Mar 31 2020 | n/a | n/a | US$34m |
| Dec 31 2019 | US$2m | US$416k | US$29m |
Compensation vs Market: Pat's total compensation ($USD7.63M) is above average for companies of similar size in the US market ($USD3.51M).
Compensation vs Earnings: Pat's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Pat Beyer (60 yo)
1.5yrs
Tenure
US$7,634,873
Compensation
Mr. Patrick J. Beyer, also known as Pat, serves as President and Chief Executive Officer of CONMED Corporation from January 01, 2025 and also serves as Director since January 01, 2025. He served as Chief O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.5yrs | US$7.63m | 0.036% $ 353.7k | |
| Executive VP | 1.7yrs | US$1.84m | 0.0096% $ 94.5k | |
| Executive Vice President of Strategy & Corporate Development | 11.2yrs | US$1.56m | 0.013% $ 127.5k | |
| Advisor | less than a year | US$3.30m | 0.0061% $ 60.1k | |
| Executive VP of Regulatory Affairs | 1.3yrs | US$1.66m | 0.0034% $ 34.0k | |
| Executive VP Global Supply Chain Management & Operations | no data | no data | no data | |
| Interim Corporate Controller & Interim Principal Accounting Officer | less than a year | no data | 0.0062% $ 61.1k | |
| Chief Information Officer | 2.7yrs | no data | no data | |
| Vice President of Compliance | no data | no data | no data | |
| Executive Vice President of Human Resources | no data | no data | no data | |
| Special Advisor | 1.5yrs | US$7.37m | 0.31% $ 3.1m | |
| President of ConMed Electrosurgery | 22yrs | US$572.33k | no data |
1.5yrs
Average Tenure
58yo
Average Age
Experienced Management: CNMD's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.5yrs | US$7.63m | 0.036% $ 353.7k | |
| Independent Director | 11yrs | US$282.13k | 0.059% $ 586.2k | |
| Independent Director | 13yrs | US$279.99k | 0.034% $ 331.1k | |
| Director | less than a year | US$161.72k | no data | |
| Independent Chairman of the Board | 6.6yrs | US$308.00k | 0.016% $ 154.3k | |
| Independent Director | 1.4yrs | US$310.73k | 0.0027% $ 26.8k | |
| Independent Director | 12yrs | US$278.75k | 0.052% $ 508.2k | |
| Independent Director | 6.8yrs | US$290.36k | 0.021% $ 211.3k |
6.7yrs
Average Tenure
62yo
Average Age
Experienced Board: CNMD's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/01 22:04 |
| End of Day Share Price | 2026/07/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CONMED Corporation is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | Barclays |
| Travis Steed | BofA Global Research |
| Kristen Stewart | CL King & Associates, Inc. |